The 36-month beta value for APTO is at 1.25. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APTO is 15.02M, and currently, shorts hold a 0.33% of that float. The average trading volume for APTO on August 28, 2024 was 91.98K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
APTO) stock’s latest price update
Aptose Biosciences Inc (NASDAQ: APTO) has seen a rise in its stock price by 0.87 in relation to its previous close of 0.39. However, the company has experienced a -14.81% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-15 that SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that its special meeting of shareholders (the “Meeting”) convened on August 15, 2024, at 1:00 p.m. (ET) has been adjourned to September 5, 2024 at 1 p.m.
APTO’s Market Performance
Aptose Biosciences Inc (APTO) has experienced a -14.81% fall in stock performance for the past week, with a -30.90% drop in the past month, and a -65.49% drop in the past quarter. The volatility ratio for the week is 13.55%, and the volatility levels for the past 30 days are at 12.33% for APTO. The simple moving average for the past 20 days is -16.75% for APTO’s stock, with a -73.73% simple moving average for the past 200 days.
Analysts’ Opinion of APTO
Many brokerage firms have already submitted their reports for APTO stocks, with Cantor Fitzgerald repeating the rating for APTO by listing it as a “Overweight.” The predicted price for APTO in the upcoming period, according to Cantor Fitzgerald is $10 based on the research report published on October 19, 2020 of the previous year 2020.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see APTO reach a price target of $12. The rating they have provided for APTO stocks is “Buy” according to the report published on September 22nd, 2020.
Maxim Group gave a rating of “Buy” to APTO, setting the target price at $16 in the report published on February 20th of the previous year.
APTO Trading at -35.55% from the 50-Day Moving Average
After a stumble in the market that brought APTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.75% of loss for the given period.
Volatility was left at 12.33%, however, over the last 30 days, the volatility rate increased by 13.55%, as shares sank -31.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.17% lower at present.
During the last 5 trading sessions, APTO fell by -15.55%, which changed the moving average for the period of 200-days by -87.96% in comparison to the 20-day moving average, which settled at $0.4637. In addition, Aptose Biosciences Inc saw -84.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APTO starting from Seizinger Bernd R., who purchase 17,000 shares at the price of $3.14 back on Sep 22 ’23. After this action, Seizinger Bernd R. now owns 17,000 shares of Aptose Biosciences Inc, valued at $53,380 using the latest closing price.
Stock Fundamentals for APTO
Current profitability levels for the company are sitting at:
- -57.52 for the present operating margin
- 0.37 for the gross margin
The net margin for Aptose Biosciences Inc stands at -56.98. The total capital return value is set at 23.25. Equity return is now at value -694.13, with -214.76 for asset returns.
Based on Aptose Biosciences Inc (APTO), the company’s capital structure generated -0.6 points at debt to capital in total, while cash flow to debt ratio is standing at -45.93. The debt to equity ratio resting at -0.38. The interest coverage ratio of the stock is -74.35.
Currently, EBITDA for the company is -52.84 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of -0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.80.
Conclusion
In conclusion, Aptose Biosciences Inc (APTO) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
